Logo image of EVT.DE

EVOTEC SE (EVT.DE) Stock Fundamental Analysis

FRA:EVT - Deutsche Boerse Ag - DE0005664809 - Common Stock - Currency: EUR

7.218  +0.38 (+5.62%)

Fundamental Rating

2

EVT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 15 industry peers in the Life Sciences Tools & Services industry. EVT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. EVT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EVT had negative earnings in the past year.
In the past year EVT has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: EVT reported negative net income in multiple years.
EVT had a positive operating cash flow in 4 of the past 5 years.
EVT.DE Yearly Net Income VS EBIT VS OCF VS FCFEVT.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

1.2 Ratios

EVT has a worse Return On Assets (-8.61%) than 80.00% of its industry peers.
The Return On Equity of EVT (-17.69%) is worse than 80.00% of its industry peers.
Industry RankSector Rank
ROA -8.61%
ROE -17.69%
ROIC N/A
ROA(3y)-0.62%
ROA(5y)0.36%
ROE(3y)-2.22%
ROE(5y)0.44%
ROIC(3y)N/A
ROIC(5y)N/A
EVT.DE Yearly ROA, ROE, ROICEVT.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10

1.3 Margins

Looking at the Gross Margin, with a value of 13.70%, EVT is doing worse than 86.67% of the companies in the same industry.
EVT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 13.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.72%
GM growth 5Y-5.57%
EVT.DE Yearly Profit, Operating, Gross MarginsEVT.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 -20 30

More info and screens

4

2. Health

2.1 Basic Checks

EVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for EVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
EVT.DE Yearly Shares OutstandingEVT.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
EVT.DE Yearly Total Debt VS Total AssetsEVT.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

EVT has an Altman-Z score of 1.43. This is a bad value and indicates that EVT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of EVT (1.43) is worse than 86.67% of its industry peers.
EVT has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.43, EVT is doing good in the industry, outperforming 73.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z 1.43
ROIC/WACCN/A
WACC6.76%
EVT.DE Yearly LT Debt VS Equity VS FCFEVT.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M 1B

2.3 Liquidity

A Current Ratio of 2.09 indicates that EVT has no problem at all paying its short term obligations.
The Current ratio of EVT (2.09) is better than 93.33% of its industry peers.
A Quick Ratio of 1.99 indicates that EVT should not have too much problems paying its short term obligations.
EVT has a better Quick ratio (1.99) than 93.33% of its industry peers.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 1.99
EVT.DE Yearly Current Assets VS Current LiabilitesEVT.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

EVT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -136.17%.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-155.56%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.17%

3.2 Future

Based on estimates for the next years, EVT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.07% on average per year.
The Revenue is expected to grow by 11.19% on average over the next years. This is quite good.
EPS Next Y74%
EPS Next 2Y37.84%
EPS Next 3Y32.3%
EPS Next 5Y20.07%
Revenue Next Year10.32%
Revenue Next 2Y12.3%
Revenue Next 3Y12.73%
Revenue Next 5Y11.19%

3.3 Evolution

EVT.DE Yearly Revenue VS EstimatesEVT.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
EVT.DE Yearly EPS VS EstimatesEVT.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5 1 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVT. In the last year negative earnings were reported.
Also next year EVT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVT.DE Price Earnings VS Forward Price EarningsEVT.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVT.DE Per share dataEVT.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

EVT's earnings are expected to grow with 32.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.84%
EPS Next 3Y32.3%

More info and screens

0

5. Dividend

5.1 Amount

EVT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOTEC SE

FRA:EVT (4/23/2025, 7:00:00 PM)

7.218

+0.38 (+5.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)04-17 2025-04-17/bmo
Earnings (Next)08-13 2025-08-13/bmo
Inst Owners55.94%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.56B
Analysts75.38
Price Target12.63 (74.98%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-260.81%
Min EPS beat(2)-417.42%
Max EPS beat(2)-104.2%
EPS beat(4)0
Avg EPS beat(4)-258.26%
Min EPS beat(4)-456.44%
Max EPS beat(4)-54.97%
EPS beat(8)1
Avg EPS beat(8)-189.93%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.08%
Min Revenue beat(2)-6.12%
Max Revenue beat(2)-6.04%
Revenue beat(4)1
Avg Revenue beat(4)-2.49%
Min Revenue beat(4)-6.12%
Max Revenue beat(4)6.43%
Revenue beat(8)4
Avg Revenue beat(8)4.18%
Revenue beat(12)7
Avg Revenue beat(12)5.6%
Revenue beat(16)11
Avg Revenue beat(16)6.25%
PT rev (1m)4.72%
PT rev (3m)4.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)133.33%
EPS NY rev (1m)-2.02%
EPS NY rev (3m)-7.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.7%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.18%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.3
P/FCF N/A
P/OCF N/A
P/B 2.65
P/tB 3.81
EV/EBITDA N/A
EPS(TTM)-1.11
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.59
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS2.19
BVpS2.73
TBVpS1.89
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.61%
ROE -17.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 13.7%
FCFM N/A
ROA(3y)-0.62%
ROA(5y)0.36%
ROE(3y)-2.22%
ROE(5y)0.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.72%
GM growth 5Y-5.57%
F-Score2
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 186.28%
Cap/Sales 22.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 1.99
Altman-Z 1.43
F-Score2
WACC6.76%
ROIC/WACCN/A
Cap/Depr(3y)201.66%
Cap/Depr(5y)169.42%
Cap/Sales(3y)23.67%
Cap/Sales(5y)19.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-155.56%
EPS Next Y74%
EPS Next 2Y37.84%
EPS Next 3Y32.3%
EPS Next 5Y20.07%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.17%
Revenue Next Year10.32%
Revenue Next 2Y12.3%
Revenue Next 3Y12.73%
Revenue Next 5Y11.19%
EBIT growth 1Y-5486.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year121.14%
EBIT Next 3Y92.58%
EBIT Next 5Y59.01%
FCF growth 1Y-271.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-111.7%
OCF growth 3Y-6.6%
OCF growth 5Y-25.26%